What is Immunome's proceeds from warrant exercises?

Immunome (IMNM) reported proceeds from warrant exercises of $0 in Q4 2025.

What does proceeds from warrant exercises mean?

This represents the cash received from the exercise of outstanding warrants by holders to purchase company common stock. It indicates the conversion of derivative instruments into equity and provides a source of non-dilutive capital relative to new offerings. A high level of exercise activity can reflect positive market sentiment regarding the company's future stock performance.

Immunome IMNM Proceeds From Warrant Exercises

Proceeds From Warrant Exercises at other companies

SELLAS Life Sciences Group, Inc.SLS

$44.08M+8,664%

Summit TherapeuticsSMMT

$0-100%

ImmunityBio, Inc.IBRX

$53.54M—

Other financials

Income statement

See full

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

See full

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

See full

Market cap$2.24B+323%

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromWarrantExercises.

The official record: Immunome’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's proceeds from warrant exercises.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's proceeds from warrant exercises?: Immunome (IMNM) reported proceeds from warrant exercises of $0 in Q4 2025.
What does proceeds from warrant exercises mean?: This represents the cash received from the exercise of outstanding warrants by holders to purchase company common stock. It indicates the conversion of derivative instruments into equity and provides a source of non-dilutive capital relative to new offerings. A high level of exercise activity can reflect positive market sentiment regarding the company's future stock performance.